SYMATESE previews COLD-X™ TECHNOLOGY, a major technological innovation in hyaluronic acids, at IMCAS.
Paris, February 06, 2025 – COLD-X™ TECHNOLOGY, a major technological innovation developed by SYMATESE in the field of hyaluronic acids, was highlighted at IMCAS through scientific communications, in the presence of Laurence Hermitte, its Scientific Director.
At IMCAS, SYMATESE is actively preparing its future launches in the USA and Europe.
These products received CE marking at the end of 2024, and were previewed at IMCAS. Two of them should receive FDA approval in the United States within 90 days, paving the way for their launch in 2025 in the USA and Europe. Thanks to its unique cold cross-linking process, this technology preserves the integrity of the original hyaluronic acid, enhancing the thermal and mechanical resistance of the resulting gels. It also optimizes the filler’s three-dimensional matrix network, guaranteeing more natural, longer-lasting clinical effects, with formulations specifically adapted to each treated area. In addition, the product features easy injection, guaranteeing an optimal experience for both practitioner and patient.
Dr Rui Avelar, from Evolus, presented the results of a prospective, randomized, double-blind study involving 140 subjects, carried out in 6 centers in the United States, comparing 2 of the 4 new formulations of HA-based injectables -ESTYME® SMOOTH AND FORM1,2– with a market-leading brand. The products tested met the key primary endpoint of non-inferiority, confirming their efficacy and performance.
According to Dr Hugues Cartier, dermatologist and Scientific Director of IMCAS: “As principal investigator of two ESTYME® clinical trials in France, I treated the first patients with two formulations as part of an international program involving over 2,000 patients in Europe, the United States and China. The clinical data presented at IMCAS corroborate the results of a study published in Dermatological Surgery Journal, which evaluated the comparative efficacy of ESTYME® FORM2 and RESTYLANE® Lidocaine in the treatment of nasolabial folds. This randomized, double-blind clinical trial included 45 patients with moderate to severe nasolabial folds. At 3 and 6 months, evaluations showed a more significant improvement with ESTYME® FORM2.
RELIVE SYMATESE KEY MOMENTS AT IMCAS 2025 with this vidéo
About SYMATESE
With 27 years of experience, SYMATESE has established itself as a leading expert in the science of tissue regeneration. Thanks to its high-performance research and technological platform integrating collagen, hyaluronic acid, silicones and thermoplastics, the company is developing innovative medical solutions that are changing patients’ lives and revolutionizing practices in some fifteen medical specialties.
These advances have also enabled us to establish prestigious collaborations on a global scale. With its cutting-edge technologies, strategic partnerships and ongoing commitment to research and development, SYMATESE is accelerating its global roll-out to 2025 already initiated in 2024, and is well placed to continue shaping the future of regenerative and aesthetic medicine.
Contacts
SYMATESE – Laurent BRONES – 06 14 31 13 57
Havas Paris – Juliette ARCOS DESLOGES – 06 07 38 35 35
1Which will be marketed in the USA under the name EVOLYSSE™ by EVOLUS Inc. USA, Brand name formerly ESTYME® LIFT
2Based on WSRS and GAIS scales
